Get to know our clinical trials
Clinical trial with SOT101 in combination with pembrolizumab to evaluate efficacy and safety in patients with selected advanced/resistant solid tumors.
THE AIM OF THE STUDY IS TO INVESTIGATE WHETHER SOT101 IN COMBINATION WITH PEMBROLIZUMAB IS ABLE TO REDUCE TUMOR SIZE. IT IS POSSIBLE THAT THIS COMBINATION TREATMENT DOES NOT PROVIDE ANY ADDITIONAL BENEFIT IN TERMS OF EFFICACY COMPARED TO PEMBROLIZUMAB ALONE.
Technical Summary
- PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM, MULTICENTER STUDY OF SOT101 IN COMBINATION WITH PEMBROLIZUMAB TO EVALUATE EFFICACY AND SAFETY IN PATIENTS WITH SELECTED ADVANCED/RESISTANT SOLID TUMORS. IMMUNOTHERAPY
- Code EudraCT: 2021-005774-25
- Protocol number: SC104
- Promoter: SOTIO
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.